John Park, MD
Medical Oncology · San Francisco, CANPI 1053375444
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $473,746 of the $558,481 with a category attached, or 84.8%. 10 manufacturers reported payments, led by AstraZeneca at 36.9% of the total. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 512 payments — averaging $1090.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$206K
- Daiichi Sankyo Inc.$145K
- Genentech USA, Inc.$106K
- Gilead$85K
- Pfizer$9K
- Immunomedics, Inc.$5K
- plus $4K from 4 others
What the payments were for
- Consulting fees$8,8982%
- Speaking & faculty fees$473,74685%
- Travel & lodging$63,39611%
- Food & beverage$12,3982%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 181 | $205,845 |
| Daiichi Sankyo Inc. | 146 | $144,576 |
| Genentech USA, Inc. | 97 | $105,678 |
| Gilead | 69 | $85,092 |
| Pfizer | 12 | $8,533 |
| Immunomedics, Inc. | 3 | $4,525 |
| Genentech, Inc. | 1 | $3,960 |
| AbbVie | 1 | $148 |
| Abbott | 1 | $104 |
| Novo Nordisk | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$558,481 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 67 | $20,293 |
| Anastrozole | 217 | $7,242 |
| Letrozole | 96 | $3,093 |
| Tamoxifen Citrate | 22 | $474 |
| Alendronate Sodium | 37 | $294 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in San Francisco
- Stephen SherwinSan Francisco$6.9M
- Kevin KimSan Francisco$176K
- Aman ChauhanSan Francisco$99K
- Ana Velazquez MananaSan Francisco$90K
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.